Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Nash Finch Q1 Profit Slips - Quick Facts

Nash-Finch Co.'s (NAFC: Quote) first-quarter 2012 reported net earnings declined to $5.5 million or $0.42 per share from $7.5 million, or $0.57 per share, with adjusted earnings, excluding significant items, dropping to $6.2 million or $0.47 per share from $9.3 million or $0.71 per share in the year-ago period. On average, 3 analysts polled by Thomson Reuters expected earnings per share of $0.55 for the quarter. Analysts' estimates typically exclude one-time items.

Total company sales were $1.06 billion, down 3.7% from $1.10 billion in the prior-year quarter. Excluding the impact of selling or closing six retail stores, total company first-quarter comparable sales slid 3.1% relative to last year.

Click here to receive FREE breaking news email alerts for Nash Finch Co and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
After moving modestly higher in morning trading, stocks showed a substantial move to the downside over the course of the trading day on Wednesday. The major averages pulled back well off their highs for the session, sliding firmly into negative territory. Ebola "czar" Ron Kain is scheduled to meet with President Barack Obama on Wednesday as he begins his efforts to coordinate the government's response to the deadly disease. Klain, who previously served as chief of staff to Vice President Joe Biden and then-Vice President Al Gore, was named as Ebola Response Coordinator last Friday. Potentially complicating the outlook for control of the Senate, the results of a SurveyUSA poll conducted for WXIA-TV in Atlanta suggest that the Georgia Senate race between Republican David Perdue and Democrat Michelle Nunn could be headed for a runoff.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.